SCHEMBL3869847

SCHEMBL3869847

O=C(Nc1ccccc1C(=O)Nc1n[nH]c2sc(C(=O)O)cc12)c1ccco1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.49
KDM4E B2RXH2 5/20 0.47
TSHR P16473 5/20 0.47
HSD17B10 Q99714 3/20 0.47
RECQL P46063 2/20 0.47
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
MAPT P10636 4/20 0.46
RXFP1 Q9HBX9 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPC1 O15118 2/20 0.46
PKM P14618 2/20 0.46
ALDH1A1 P00352 3/20 0.46
GAA P10253 3/20 0.46
HPGD P15428 3/20 0.46
TP53 P04637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1777256 0.87 RXFP1 (0.47) MAPK1KDM4ETSHRHSD17B10RECQL
SCHEMBL3866786 0.86 KDM4E (0.48) KDM4EKMT2AMEN1MAPTRXFP1
SCHEMBL3876563 0.84 RXFP1 (0.46) KDM4ERXFP1PKMALDH1A1HPGD
SCHEMBL3870804 0.84 NPC1 (0.45) HSD17B10KMT2AMEN1MAPTRXFP1
SCHEMBL3872653 0.84 ALDH1A1 (0.43) KDM4EKMT2AMEN1MAPTRXFP1
SCHEMBL3872325 0.83 KCNK3 (0.40) KDM4EKMT2AMEN1MAPTNPC1
SCHEMBL3866586 0.83 POLB (0.42) KDM4EHSD17B10KMT2AMEN1MAPT
SCHEMBL1780074 0.83 SMN1; SMN2 (0.43) MAPK1KDM4ETSHRHSD17B10RECQL
SCHEMBL3865316 0.82 INSR (0.48) NPC1RAB9ASMN1; SMN2
SCHEMBL3875203 0.82 TSHR (0.51) MAPK1KDM4ETSHRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP claimed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US claimed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP claimed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO claimed
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 MAPK1 66/4885KDM4E 2856/4885TSHR 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.